Literature DB >> 26920893

Everything Old Is New Again: Using Nelfinavir to Radiosensitize Rectal Cancer.

Raymond E Meyn1, Sunil Krishnan2, Heath D Skinner3.   

Abstract

Repurposing agents approved for other indications to radiosensitize tumors may be advantageous. The study by Hill and colleagues utilizes nelfinavir, an HIV protease inhibitor (PI), in combination with radiotherapy in rectal cancer in a prospective study. This combination may improve tumor perfusion and regression compared with radiotherapy alone. ©2016 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26920893      PMCID： PMC5061034          DOI： 10.1158/1078-0432.CCR-16-0024

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  11 in total

1.  HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling.

Authors:  Yang Yang; Takayuki Ikezoe; Tamotsu Takeuchi; Yoshihiro Adachi; Yuji Ohtsuki; Seisho Takeuchi; H Phillip Koeffler; Hirokuni Taguchi
Journal:  Cancer Sci       Date:  2005-07       Impact factor: 6.716

2.  Nelfinavir inhibits regulated intramembrane proteolysis of sterol regulatory element binding protein-1 and activating transcription factor 6 in castration-resistant prostate cancer.

Authors:  Min Guan; Kristen Fousek; Warren A Chow
Journal:  FEBS J       Date:  2012-05-21       Impact factor: 5.542

3.  The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients.

Authors:  N P West; M Dattani; P McShane; G Hutchins; J Grabsch; W Mueller; D Treanor; P Quirke; H Grabsch
Journal:  Br J Cancer       Date:  2010-04-20       Impact factor: 7.640

4.  Tumor vascular changes mediated by inhibition of oncogenic signaling.

Authors:  Naseer Qayum; Ruth J Muschel; Jae Hong Im; Lukxmi Balathasan; Cameron J Koch; Sonal Patel; W Gillies McKenna; Eric J Bernhard
Journal:  Cancer Res       Date:  2009-07-21       Impact factor: 12.701

5.  HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest.

Authors:  Wei Jiang; Peter J Mikochik; Jin H Ra; Hanqin Lei; Keith T Flaherty; Jeffrey D Winkler; Francis R Spitz
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

6.  Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir.

Authors:  Joong Sup Shim; Rajini Rao; Kristin Beebe; Len Neckers; Inkyu Han; Rita Nahta; Jun O Liu
Journal:  J Natl Cancer Inst       Date:  2012-10-05       Impact factor: 13.506

7.  Clinical Trial of Oral Nelfinavir before and during Radiation Therapy for Advanced Rectal Cancer.

Authors:  Esme J Hill; Corran Roberts; Jamie M Franklin; Monica Enescu; Nicholas West; Thomas P MacGregor; Kwun-Ye Chu; Lucy Boyle; Claire Blesing; Lai-Mun Wang; Somnath Mukherjee; Ewan M Anderson; Gina Brown; Susan Dutton; Sharon B Love; Julia A Schnabel; Phil Quirke; Ruth Muschel; William G McKenna; Michael Partridge; Ricky A Sharma
Journal:  Clin Cancer Res       Date:  2016-02-09       Impact factor: 12.531

8.  Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy.

Authors:  Nabendu Pore; Anjali K Gupta; George J Cerniglia; Zibin Jiang; Eric J Bernhard; Sydney M Evans; Cameron J Koch; Stephen M Hahn; Amit Maity
Journal:  Cancer Res       Date:  2006-09-15       Impact factor: 12.701

9.  Nelfinavir, an HIV protease inhibitor, induces apoptosis and cell cycle arrest in human cervical cancer cells via the ROS-dependent mitochondrial pathway.

Authors:  Tong Xiang; Lanying Du; Petra Pham; Bo Zhu; Shibo Jiang
Journal:  Cancer Lett       Date:  2015-04-29       Impact factor: 9.756

10.  NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines.

Authors:  Y Yang; T Ikezoe; C Nishioka; K Bandobashi; T Takeuchi; Y Adachi; M Kobayashi; S Takeuchi; H P Koeffler; H Taguchi
Journal:  Br J Cancer       Date:  2006-11-28       Impact factor: 7.640
View more
  3 in total

1.  The HIV protease inhibitor, nelfinavir, as a novel therapeutic approach for the treatment of refractory pediatric leukemia.

Authors:  Vanessa Meier-Stephenson; Justin Riemer; Aru Narendran
Journal:  Onco Targets Ther       Date:  2017-05-16       Impact factor: 4.147

Review 2.  Repurposing non-oncology small-molecule drugs to improve cancer therapy: Current situation and future directions.

Authors:  Leilei Fu; Wenke Jin; Jiahui Zhang; Lingjuan Zhu; Jia Lu; Yongqi Zhen; Lan Zhang; Liang Ouyang; Bo Liu; Haiyang Yu
Journal:  Acta Pharm Sin B       Date:  2021-09-10       Impact factor: 11.413

3.  Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.

Authors:  A Besse; S C Stolze; L Rasche; N Weinhold; G J Morgan; M Kraus; J Bader; H S Overkleeft; L Besse; C Driessen
Journal:  Leukemia       Date:  2017-07-05       Impact factor: 11.528
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.